Amphastar Pharmaceuticals, Inc. $AMPH Stake Raised by CX Institutional

Key Points

• CX Institutional increased its stake in Amphastar Pharmaceuticals by 220.5% during the 2nd quarter, now holding 263,283 shares valued at over $6 million.
• Several other institutional investors also significantly raised their positions in Amphastar, leading to institutional ownership now at 65.09% of the company's stock.
• Amphastar's stock is currently trading at $27.64 with a market cap of $1.28 billion, experiencing gains and undergoing recent analyst upgrades with mixed price targets.

CX Institutional boosted its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 220.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 263,283 shares of the company's stock after acquiring an additional 181,136 shares during the quarter. CX Institutional owned about 0.56% of Amphastar Pharmaceuticals worth $6,045,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AMPH. Millennium Management LLC raised its position in Amphastar Pharmaceuticals by 238.5% in the first quarter. Millennium Management LLC now owns 868,551 shares of the company's stock worth $25,179,000 after acquiring an additional 611,995 shares in the last quarter. TD Asset Management Inc raised its position in Amphastar Pharmaceuticals by 20.2% in the first quarter. TD Asset Management Inc now owns 2,212,142 shares of the company's stock worth $64,130,000 after acquiring an additional 371,856 shares in the last quarter. Royce & Associates LP raised its position in Amphastar Pharmaceuticals by 2,684.3% in the first quarter. Royce & Associates LP now owns 247,858 shares of the company's stock worth $7,185,000 after acquiring an additional 238,956 shares in the last quarter. Boston Trust Walden Corp increased its stake in Amphastar Pharmaceuticals by 24.2% in the 1st quarter. Boston Trust Walden Corp now owns 1,215,624 shares of the company's stock worth $35,241,000 after purchasing an additional 236,704 shares in the last quarter. Finally, Epoch Investment Partners Inc. increased its stake in Amphastar Pharmaceuticals by 14.5% in the 1st quarter. Epoch Investment Partners Inc. now owns 1,261,307 shares of the company's stock worth $36,565,000 after purchasing an additional 160,034 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.

Amphastar Pharmaceuticals Trading Up 0.7%

Shares of NASDAQ AMPH opened at $27.64 on Friday. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of 10.35 and a beta of 0.80. The business has a 50 day simple moving average of $26.25 and a 200 day simple moving average of $25.58. Amphastar Pharmaceuticals, Inc. has a 52 week low of $20.39 and a 52 week high of $53.96. The company has a debt-to-equity ratio of 0.80, a quick ratio of 2.21 and a current ratio of 3.29.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on AMPH shares. Needham & Company LLC raised Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 price target on the stock in a research note on Tuesday, August 12th. Piper Sandler dropped their price target on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating on the stock in a research note on Friday, August 8th. Finally, Bank of America lifted their target price on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a "neutral" rating in a research note on Tuesday, August 26th. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $31.60.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.